SCHEMBL26099790

SCHEMBL26099790

COc1ccc(CN(C)c2cc(Nc3cccc(-c4ccc(C5OCCO5)cn4)c3)nn3c(C(=O)O)cnc23)cc1.[KH]

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ TYK2 P29597 4/20 0.37
▸ PDE4D Q08499 1/20 0.37
▸ AURKA O14965 5/20 0.34
▸ BRAF P15056 2/20 0.32
▸ KDM4E B2RXH2 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ LMNA P02545 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ KDM1A O60341 1/20 0.32
▸ FYN P06241 2/20 0.32
▸ PDE1B Q01064 1/20 0.32
▸ FGFR3 P22607 1/20 0.31
▸ KDR P35968 1/20 0.31
▸ CNR2 P34972 1/20 0.31
▸ NPC1 O15118 1/20 0.31
▸ RAB9A P51151 1/20 0.31
▸ EGFR P00533 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26510925 0.99 TYK2 (0.37) TYK2PDE4DAURKABRAFKDM4E
Potassium SCHEMBL30392578 0.99 TYK2 (0.37) TYK2PDE4DAURKABRAFKDM4E
Potassium Ion SCHEMBL30391293 0.93 TYK2 (0.35) TYK2PDE4DAURKABRAFKDM4E
Potassium Ion SCHEMBL26098159 0.93 TYK2 (0.35) TYK2PDE4DAURKABRAFKDM4E
SCHEMBL30392961 0.92 FAAH (0.37) TYK2PDE4DAURKABRAFLMNA
SCHEMBL26100287 0.92 FAAH (0.37) TYK2PDE4DAURKABRAFLMNA
SCHEMBL26100963 0.91 TYK2 (0.40) TYK2PDE4D
SCHEMBL26101565 0.90 TYK2 (0.39) TYK2PDE4DAURKACNR2
SCHEMBL30392681 0.90 TYK2 (0.33) TYK2PDE4DAURKABRAFPDE1B
SCHEMBL30392105 0.90 TYK2 (0.33) TYK2PDE4DAURKABRAFKDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250051338-A1 TYK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-02-13 — — US disclosed
WO-2023076161-A1 TYK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-05-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250051338-A1 TYK2 DEGRADERS AND USES THEREOF TYK2, DYRK2, DYRK1A TYK2 1/4885PDE4D 4649/4885AURKA 82/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback